Policy Statement: Safinamide as add on therapy to Levodopa alone or in combination to other treatments in adult patients with idiopathic Parkinson’s Disease

<table>
<thead>
<tr>
<th>Policy No:</th>
<th>PCN 321-2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of Issue</td>
<td>January 2018</td>
</tr>
<tr>
<td>Review Date:</td>
<td>January 2021</td>
</tr>
</tbody>
</table>

(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)

**Recommendations:**

The Prescribing Clinical Network does not recommend Safinamide as add on therapy to Levodopa, alone or in combination to other treatments in adult patients with idiopathic Parkinson’s Disease.

Safinamide will be considered **BLACK** on the traffic light status for all new patients as there are more cost effective treatment options available.

Patients whose treatment with safinamide was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until the patient and their NHS consultant consider it appropriate to stop.

**Key Consideration:**

- Evidence base limited with no comparative studies with the other treatments in the same class
- Dyskinesia most commonly reported adverse effect in clinical trials, noting that this may worsen in patients with pre-existing dyskinesia.

**Date taken to Prescribing Clinical Network**

10th January 2018

**Agreed by PCN members**

22nd January 2018